The acquisition provides GSK access to Camlipixant, a P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
The committee voted 16 to 1 that available data support the safety and effectiveness of Paxlovid for treating mild to moderate COVID-19 in adult patients at high risk for progression to severe illness.